Conatus Pharmaceuticals Inc. Gains 29.34%
Thu, May 14, 2020 at 05:30 PM
Conatus Pharmaceuticals Inc. (CNAT:NASDAQ) rocketted at $0.63, representing a gain of 29.3%. On Wed 13 May 20, CNAT:NASDAQ hit a New 2-Week High of $0.48. The stock got featured on our News Catalysts scanner on Sat 02 May 20 at 04:55 AM in the 'EARNINGS' category. From Wed 29 Apr 20, the stock recorded 60.00% Up Days and 45.45% Green Days
The stock spiked on Wed 06 May 20 at $0.54 with a volume of 5M+.
About Conatus Pharmaceuticals Inc. (CNAT:NASDAQ)
Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease.
Top 10 Gainers:
- Applied DNA Sciences, Inc. (APDN:NASDAQ), 71.09%
- Glory Star New Media Group Holdings Limited (GSMG:NASDAQ), 45.49%
- Allogene Therapeutics, Inc. (ALLO:NASDAQ), 35.96%
- Conatus Pharmaceuticals Inc. (CNAT:NASDAQ), 29.34%
- Diffusion Pharmaceuticals Inc. (DFFN:NASDAQ), 28.46%
- Cellectis S.A. (CLLS:NASDAQ), 27.08%
- AIM ImmunoTech Inc. (AIM:NYSEMKT), 25.11%
- Entercom Communications Corp. (ETM:NYSE), 24.84%
- Alpha Pro Tech, Ltd. (APT:NYSEMKT), 24.81%
- Genius Brands International, Inc. (GNUS:NASDAQ), 24.43%